FirebrickPharma

Investor Update

27 JULY 2026

Peter Molloy

Executive Chairman

ASX: FRE
firebrickpharma.com

Authorised for release by the
Board of Firebrick Pharma Limited

IMPORTANT NOTICE AND DISCLAIMER

This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Firebrick Pharma Limited (**Firebrick**). This presentation is intended only for those persons to whom it is delivered personally by or on behalf of Firebrick. By attending this presentation, you represent and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document (as defined in the Corporations Act 2001 (Cth) (**Corporations Act**)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are outside Australia, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this document and any copies and do not provide this document to any other person. This presentation is strictly confidential and is intended for the exclusive benefit of the person to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Firebrick. The recipient shall not disclose any of the information contained in this presentation to any other person without the prior written consent of Firebrick, which may be withheld in its absolute discretion.

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. Neither Firebrick, its related bodies corporate, shareholders or affiliates, nor any of their respective officers, directors, employees, related bodies corporate, affiliates, agents or advisers makes any representations or warranties that this presentation is complete or that it contains all material information about Firebrick or which a prospective investor or purchaser may require in evaluating a possible investment in Firebrick or an acquisition of its shares. To the maximum extent permitted by law, none of those persons accept any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based upon information known and assumptions made as of the date of this presentation. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, clinical trials, required regulatory approvals, future earnings or financial position or performance are also forward looking statements. These statements are subject to internal and external risks and uncertainties that may have a material effect on future business. Actual results may differ materially from any future results or performance expressed, predicted or implied by the statements contained in this presentation. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future. No person is under any obligation to update this presentation at any time after its release to you.

The provision of this presentation is not a representation to you or any other person that an offer of securities will be made. Any prospective transaction would be undertaken solely on the basis of disclosure documentation prepared in accordance with applicable securities laws and regulations. The information presented in this presentation may differ materially in both content and presentation from that presented in any disclosure document prepared in connection with any prospective transaction. Firebrick reserves the right to alter the information contained in this presentation in any disclosure document prepared in respect of any prospective transaction from the form of this presentation accordingly.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Firebrick and neither this presentation nor any of the information contained herein shall form the basis of any contract or commitment. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

This presentation may not be reproduced or redistributed to any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party without the prior approval of Firebrick. All references to dollars, cents or $ in this presentation are to Australian currency, unless otherwise stated.

In receiving this presentation, each recipient agrees to the foregoing terms and conditions.

Board and Senior Management

Dr Peter Molloy

CEO, Chair & Founder

Dr Stephen Goodall

COO, Director & Founder

Rick Legleiter

Non-Executive Director

Al Moghaddam

Non-Executive Director

Nilesh Wadhwa

Head of Business Development & Licensing

Dr Simon Tucker

Chief Scientific Officer

Dr Monique Baldwin

Head of Regulatory Affairs

Kam Watson

Marketing Services Manager

Capital Structure

Financial Information (ASX: FRE)	A$
Share price (52-week range}	$0.027-0.085
Shares on Issue	285.2m
Market cap (20 July 2026)	$8.55m
Cash balance (30 Jun 2026)	$1.32m
Quarterly burn (FY26 average)	$0.65m

Major shareholders (20 July 2026)	
P Molloy (CEO, Chairman)	11.2%
S Goodall (COO, Director)	10.9%
GZ Family Holdings (Family Office)	8.5%
Pharma Nutria Inc (Strategic Investor)	4.5%
Top 10	47%

Share Price – Last 6 Months

Quarterly Financials

4C (cash basis)







* Excludes one-of $146k w/sale pipeline filling in Singapore

Product Overview: Nasodine® Nasal Spray

Nasodine®
Nasal Spray

- The world's **first nasal spray that kills germs,** including all viruses and bacteria that cause nasal infections
  - Inactivates all pandemic viruses tested
  - No evident potential for viral or bacterial resistance
- A **nasal sanitiser/antiseptic** for:
  - **Protection against airborne viruses** when people around you have symptoms
  - **Early treatment of the Common Cold**
  - **Front line pandemic defence** for healthcare workers
  - **Airlines, cruise lines and every business** that wants to reduce transmission risk
  - **Air travellers, commuters, doctors, hospitals, teachers, mothers** and anyone else worried about airborne germs

Singapore Retail Packaging

The nasal sanitiser with wide potential

A timely, versatile innovation with massive commercial potential and health benefits

85 billion days of misery from 17 billion colds p.a., could be saved, with early treatment with Nasodine

In a busy, crowded **post-COVID world**, protection from **other people's viruses is essential** (esp. in Asia)

21% of Nasodine buyers use it for **sinusitis** which affects **5-12% of the world** and is often resistant to treatment

Every business will benefit from the **reduced downtime due to URTI**

Finally, **doctors** have a product that **targets the viral cause of URTI**, to deflect antibiotic requests

Hospitals want it to stop **nasal shedding of MRSA**, which causes costly (or even fatal) surgical site infections



Governments need to stockpile it for frontline protection before the next **pandemic** or **bioweapon**

Massive untapped military potential: Nasodine should be standard issue worldwide for every soldier (and sailor)

The power of a broad-spectrum, safe antiseptic: **povidone-iodine.** For the first time in a nasal spray, underpinned by Firebrick-owned **patents & published studies** specifically on Nasodine Nasal Spray

Supported commercially by patents


TREATMENT AND PREVENTION OF THE COMMON COLD USING POVIDONE-IODINE

AU2014206143
5 February 2015

Peter Molloy
Stephen Goodall
Inventors

Firebrick Pharma Limited
Applicant

Figure 1. Viral Load in Nose from HRV Model

Figure 2. Cold Symptom Scores from HRV Model

Australian Government
IP Australia

FirebrickPharma

ABSTRACT

The present invention provides a method of treating the common cold in a human subject. The method comprises applying to the nasal passages of the human subject at ambient temperature, an effective amount of a pharmaceutical preparation comprising povidone iodine (PVP-I) at a concentration of greater than 0.10% w/v and in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers.


U.S. Patent No. 11,246,887
Issued February 15, 2022

The United States of America

Peter Molloy
Stephen Goodall
Inventors

Firebrick Pharma Limited
Assignee

PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES

FirebrickPharma

ABSTRACT

This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.

Safety established in published studies

Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial. Polasek, T. M., & Friedland, P. L. (2025). *Frontiers in Medicine*,12, 1565069. https://pubmed.ncbi.nlm.nih.gov/40538402

Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2. Friedland, P. L., & Tucker, S. (2024). *The Laryngoscope*, 134(9), 3947-3952. https://pubmed.ncbi.nlm.nih.gov/38554057

Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine). Friedland, P. L., Polasek, T. M., & Topliss, D. (2024). *In International Forum of Allergy & Rhinology* (Vol. 14, No. 9) https://pubmed.ncbi.nlm.nih.gov/38869489

In vitro Nasodine can be an effective antibiofilm agent for biofilms that may cause CRS. Hale, S. J. *et al.* (2023). *The Laryngoscope*, 133(10), 2490-2495. https://doi.org/10.1002/lary.30558

In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray. Friedland, P. *et al.* (2022). *Australian Journal of Otolaryngology*. 2022, 5, (0), pp. 1-9 https://www.theajo.com/article/view/4466/html

In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells. Ramezanpour, M. *et al.* (2020). *International forum of allergy & rhinology* (Vol. 10, No. 10, pp. 1141-1148). https://doi.org/10.1002/alr.22575

Current commercial status

- Marketing of Nasodine® Nasal Spray
  - Launched online in **USA** in Apr-2024 and in **Singapore** in Jun-2024
  - **Approval in Indonesia** announced March 2026
  - **Philippines approval** applied for and expected in FY27
  - Expected to be approved or on sale in **10 markets** within 3 years
- Manufacturing sites:
  - **Australia, Philippines and USA**
- Portfolio expansion underway
  - **Nasodine Throat Spray** launched in Singapore Jan 2026; potential roll-out in US later this year
  - **3rd Nasodine product** expected in 2026



In a post-pandemic world, Nasodine could be a commercial blockbuster?

Yes, but it faces some obstacles – the most important of which is regulatory

- **Many markets (e.g., Australia) do not have an approval pathway for a ‘nasal antiseptic’**
  - In such markets, regulators **classify it as a medicine** (drug), even though it works topically (not systemically); this makes the evidentiary burden very high, especially for an indication like the common cold.
- **USA is an exception:** povidone-iodine is not classified as a drug if there is no therapeutic claim made
  - Nasodine is sold as a **‘cosmetic’ (nasal cleanser)** and makes no germ-killing claims
  - USA could be an important market, especially if there’s **another pandemic**
- **Most S.E. Asian countries classify Nasodine as an ‘antiseptic’**
  - Means low regulatory burden, faster approval
  - S.E. Asia and similar markets are early targets

Price and volume considerations

- Nasodine is relatively inexpensive
  - Nasal Spray 25mL sells for around A$27-36 per unit*
  - Under current license agreements, Firebrick receives approx. A$2-3 per unit as a license fee
  - Implied break-even sales volume = 1 million units, based on current operating costs
- This will need time and some larger markets to be successful
  - E.g., USA, Philippines or Indonesia
- Or another pandemic?
  - Nasodine Nasal Spray is the only proven-safe, commercial-scale, nasal sanitiser

* USA RRP: US$24.99 per 25mL
Singapore RRP: S$24.90 per 25mL

In summary

- Past
  - After more than 10 years of R&D, we have successfully developed and patented the world's first nasal spray that kills viruses, Nasodine Nasal Spray, now in early commercialisation
  - Nasodine was initially developed as a treatment for the Common Cold, but post-pandemic, it has multiple market opportunities beyond that one indication
  - Before the next pandemic "the world needs Nasodine"; a nasal sanitiser that is proven safe, inexpensive, easily deployable, and no evident potential for viral resistance
- Future
  - Firebrick has completed its core R&D and has no substantial forward clinical risk
  - Nasodine is a brand that has great potential but is at an early stage of commercialisation
  - Its global success driven by licensing to committed partners in markets where it can be sold without undue regulatory barriers
  - Sales growth and long-term value creation will come by adding new markets, building sales through licensees over time and introducing new products (MARKETS x TIME x PRODUCTS)

Plans and catalysts

Achievements FY26	Plans for FY27
Manufacturing in the Philippines of Nasodine Nasal Spray, and **registration filed with PFDA**	**Launch in Indonesia** of Nasodine Nasal Spray and licensing deal
Nasodine Nasal Spray **approval gained in Indonesia** (largest market in SE Asia)	**Approval and launch in the Philippines** (2nd largest market in SE Asia)
2nd Nasodine product: **Nasodine Throat Spray** launched in Singapore in Jan 2026	Announcement of a **3rd Nasodine product**
Rapid growth in US sales of the nasal spray	**Registration approval filings in multiple other markets**
New executive appointed to drive **global licensing program**	**US retail launch** to accelerate sales and profit growth in the US business

FirebrickPharma

For more information:
www.firebrickpharma.com

ASX: FRE